×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ASND – ascendis pharma a/s - american depositary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ASND
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/12
06:37 pm
asnd
What Ascendis Pharma (ASND)'s Phase 2 COACH Combo Data Means For Shareholders [Yahoo! Finance]
Low
Report
What Ascendis Pharma (ASND)'s Phase 2 COACH Combo Data Means For Shareholders [Yahoo! Finance]
1/10
01:06 am
asnd
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/9
06:01 pm
asnd
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference
1/9
07:18 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Medium
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
1/8
04:56 pm
asnd
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) [Yahoo! Finance]
Medium
Report
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) [Yahoo! Finance]
1/8
04:01 pm
asnd
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
Low
Report
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)
1/7
03:02 pm
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its "buy" rating reaffirmed by analysts at Cowen Inc.
1/7
10:58 am
asnd
Ascendis Pharma A/S (NASDAQ:ASND) had its "buy" rating reaffirmed by analysts at TD Cowen. They now have a $325.00 price target on the stock.
Low
Report
Ascendis Pharma A/S (NASDAQ:ASND) had its "buy" rating reaffirmed by analysts at TD Cowen. They now have a $325.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2025
04:01 pm
ASND
ascendis pharma a/s - american depositary shares
MISS
Report
3.1%
ascendis pharma a/s - american depositary shares
8/7/2025
04:01 pm
ASND
ascendis pharma a/s - american depositary shares
BEAT
Report
0.6%
ascendis pharma a/s - american depositary shares
5/1/2025
04:01 pm
ASND
ascendis pharma a/s - american depositary shares
MISS
Report
2.7%
ascendis pharma a/s - american depositary shares
2/12/2025
04:01 pm
ASND
ascendis pharma a/s - american depositary shares
BEAT
Report
13.0%
ascendis pharma a/s - american depositary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/13
02:02 pm
asnd
Form 144 Ascendis Pharma A/S Filed by: MIKKELSEN JAN MOLLER
Low
Report
Form 144 Ascendis Pharma A/S Filed by: MIKKELSEN JAN MOLLER
1/12
06:04 am
asnd
Form 6-K Ascendis Pharma A/S For: Jan 12
Medium
Report
Form 6-K Ascendis Pharma A/S For: Jan 12
1/9
06:01 am
asnd
Form 6-K Ascendis Pharma A/S For: Jan 08
Medium
Report
Form 6-K Ascendis Pharma A/S For: Jan 08
12/30
04:15 pm
asnd
Form 6-K Ascendis Pharma A/S For: Dec 30
Low
Report
Form 6-K Ascendis Pharma A/S For: Dec 30
12/10
04:15 pm
asnd
Form 6-K Ascendis Pharma A/S For: Dec 10
Medium
Report
Form 6-K Ascendis Pharma A/S For: Dec 10
12/4
05:07 pm
asnd
Form 144 Ascendis Pharma A/S Filed by: JENSEN MICHAEL WOLFF
Low
Report
Form 144 Ascendis Pharma A/S Filed by: JENSEN MICHAEL WOLFF
12/2
05:04 pm
asnd
Form 144 Ascendis Pharma A/S Filed by: MIKKELSEN JAN MOLLER
Low
Report
Form 144 Ascendis Pharma A/S Filed by: MIKKELSEN JAN MOLLER
12/2
04:54 pm
asnd
Form 144 Ascendis Pharma A/S Filed by: SPROGOE KENNETT
Low
Report
Form 144 Ascendis Pharma A/S Filed by: SPROGOE KENNETT
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/20
Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Oppenheimer Holdings Inc. from $199.00 to $219.00. They now have an "outperform" rating on the stock.
9.1%
11/18 Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results 6.3%
6/3 Ascendis Pharma A/S (NASDAQ: ASND) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $223.00 price target on the stock, up previously from $219.00. 6.0%
6/14 Form 6-K Ascendis Pharma A/S For: Jun 14 5.5%
11/22 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.3%
12/17 Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Morgan Stanley from $134.00 to $140.00. They now have an "overweight" rating on the stock. 4.6%
12/25 Ascendis Pharma A/S (NASDAQ: ASND) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.1%
10/10 Form 6-K Ascendis Pharma A/S For: Oct 10 3.8%
11/20 Edited Transcript of ASND earnings conference call or presentation 18-Nov-19 9:30pm GMT [Yahoo! Finance News] 3.7%
4/14 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.6%
11/18 Ascendis Pharma A/S Reports Third Quarter 2019 Financial Results 6.3%
6/3 Ascendis Pharma A/S (NASDAQ: ASND) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $223.00 price target on the stock, up previously from $219.00. 6.0%
6/14 Form 6-K Ascendis Pharma A/S For: Jun 14 5.5%
11/22 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.3%
12/17 Ascendis Pharma A/S (NASDAQ: ASND) had its price target raised by analysts at Morgan Stanley from $134.00 to $140.00. They now have an "overweight" rating on the stock. 4.6%
12/25 Ascendis Pharma A/S (NASDAQ: ASND) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.1%
10/10 Form 6-K Ascendis Pharma A/S For: Oct 10 3.8%
11/20 Edited Transcript of ASND earnings conference call or presentation 18-Nov-19 9:30pm GMT [Yahoo! Finance News] 3.7%
4/14 Ascendis Pharma A/S (NASDAQ: ASND) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 3.6%
TOP News Decliners
6/26
Form 6-K Ascendis Pharma A/S For: Jun 26
-9.8%
9/26 Ascendis Pharma A/S Announces Upcoming Investor Presentation in October -7.5%
4/20 Form 6-K Ascendis Pharma A/S For: Apr 20 -5.8%
5/30 Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -5.4%
8/29 Ascendis Pharma A/S (ASND) Q2 2019 Earnings Call Transcript [The Motley Fool] -5.2%
3/31 Sofinnova Investments Strengthens Executive Team with Promotions of Maha Katabi, PhD, CFA and Sarah Bhagat, PhD -5.0%
11/15 Form 6-K Ascendis Pharma A/S For: Nov 15 -4.2%
7/1 Form 6-K Ascendis Pharma A/S For: Jul 01 -3.9%
4/2 Ascendis Pharma A/S (ASND) Q4 2019 Earnings Call Transcript [The Motley Fool] -3.6%
6/10 Form SC 13G/A Ascendis Pharma A/S Filed by: PRICE T ROWE ASSOCIATES INC /MD/ -3.5%
9/26 Ascendis Pharma A/S Announces Upcoming Investor Presentation in October -7.5%
4/20 Form 6-K Ascendis Pharma A/S For: Apr 20 -5.8%
5/30 Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2019 Results - Earnings Call Transcript [Seeking Alpha] -5.4%
8/29 Ascendis Pharma A/S (ASND) Q2 2019 Earnings Call Transcript [The Motley Fool] -5.2%
3/31 Sofinnova Investments Strengthens Executive Team with Promotions of Maha Katabi, PhD, CFA and Sarah Bhagat, PhD -5.0%
11/15 Form 6-K Ascendis Pharma A/S For: Nov 15 -4.2%
7/1 Form 6-K Ascendis Pharma A/S For: Jul 01 -3.9%
4/2 Ascendis Pharma A/S (ASND) Q4 2019 Earnings Call Transcript [The Motley Fool] -3.6%
6/10 Form SC 13G/A Ascendis Pharma A/S Filed by: PRICE T ROWE ASSOCIATES INC /MD/ -3.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: